RedHill Biopharma (RDHL) Cash & Equivalents: 2011-2025
Historic Cash & Equivalents for RedHill Biopharma (RDHL) over the last 12 years, with Jun 2025 value amounting to $4.6 million.
- RedHill Biopharma's Cash & Equivalents fell 17.09% to $4.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $4.6 million, marking a year-over-year decrease of 17.09%. This contributed to the annual value of $4.6 million for FY2024, which is 17.09% down from last year.
- Per RedHill Biopharma's latest filing, its Cash & Equivalents stood at $4.6 million for Q2 2025, which was down 0.00% from $4.6 million recorded in Q4 2024.
- Over the past 5 years, RedHill Biopharma's Cash & Equivalents peaked at $76.0 million during Q2 2021, and registered a low of $4.6 million during Q4 2024.
- For the 3-year period, RedHill Biopharma's Cash & Equivalents averaged around $9.7 million, with its median value being $5.6 million (2024).
- As far as peak fluctuations go, RedHill Biopharma's Cash & Equivalents soared by 78.53% in 2021, and later crashed by 72.11% in 2023.
- Quarterly analysis of 5 years shows RedHill Biopharma's Cash & Equivalents stood at $29.5 million in 2021, then tumbled by 32.25% to $20.0 million in 2022, then slumped by 72.11% to $5.6 million in 2023, then dropped by 17.09% to $4.6 million in 2024, then dropped by 17.09% to $4.6 million in 2025.
- Its Cash & Equivalents was $4.6 million in Q2 2025, compared to $4.6 million in Q4 2024 and $5.6 million in Q2 2024.